programmed cell death 10Genealiases: CCM3 · TFAR15
Q-omics provides the consensus-scored PDCD10 profile across patient tissues and cancer cell-line models. PDCD10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PDCD10 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, PDCD10 RNA expression shows 19,686 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where PDCD10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDCD10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDCD10 survival associations across molecular data types. PDCD10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDCD10 RNA expression–survival associations across cancer types. High PDCD10 expression shows unfavorable associations in PAAD, LIHC, SCLC and ACC, but favorable associations in KIRC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PDCD10 RNA expression.
This table summarizes PDCD10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDCD10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDCD10 shows higher tumor expression in HNSC, BLCA, LIHC, LUSC, BRCA and CHOL. The HNSC box plot shows higher PDCD10 RNA expression in tumor versus normal tissue (log2 FC = +1.067, t-test p < 0.001).
This table shows molecular features associated with PDCD10 in patient tissues and cancer cell lines. In patient samples, PDCD10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PDCD10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
